Cardiovascular disease prevention and the rise in dementia

QJM: An International Journal of Medicine

Volumn 105, Issue 1, 2012, Pages 93-97

  Thompson, G R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN E4; ATORVASTATIN; FOLIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN;

ALLELE; ALZHEIMER DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEMENTIA; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; HYPERCHOLESTEROLEMIA; INCIDENCE; ISCHEMIC HEART DISEASE; LIFE EXPECTANCY; LIFESTYLE MODIFICATION; LONGEVITY; MORTALITY; NOTE; PATHOGENESIS; PILL; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; STROKE; UNITED KINGDOM;

EID: 83755183507     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcr181     Document Type: Note

References (23)

1. Office for National Statistics. [http://www.statistics.gov.uk/cci/nugget_print.asp?ID=168] Accessed 25 May 2011.
2. Coronary heart disease statistics. British Heart Foundation Statistics Database. 2007 edn. [www.heartstats.org] Accessed 25 May 2011.
3. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364:937-52.
4. Alzheimer's Society. Statistics. [http://alzheimers.org.uk/site/scripts/document_pdf.php?documentID=341] Accessed 25 May 2011.
5. Alzheimer's Disease International. [http://www.alz.co.uk/adi/pdf/prevalence.pdf] Accessed 25 May 2011.
6. Reitz C, Brayne C, Mayeux R. Epidemiology of Alzheimer Disease. Nat Rev Neurol 2011; 7:137-52.
7. Wu K, Bowman R, Welch AA, Luben R, Wareham N, Khaw K-T, et al. Apolipoprotein E polymorphisms, dietary fat and fibre, and serum lipids: the EPIC Norfolk study. Eur Heart J 2007; 28:2930-36.
8. Genin E, Hannequin D, Wallon D, Sleegers K, Hiltunen M, Combarros O, et al. APOE and Alzheimer disease: a major gene with semi-dominant inheritance. Mol Psychiatry 2011; 16:903-7.
9. UK National Screening Committee. [http://www.screening.nhs.uk/alzheimers] Accessed 25 May 2011.
10. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-78.
11. Cholesterol Treatment Trialists' (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: ameta-analysis of data from 170 000 participants in 26 randomised trials. Lancet 2010; 376:1670-81.
12. Taylor F, Ward K, Moore TH, Burke M, Davey Smith G, Casas JP, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev 2011; 1:CD004816.
13. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326:1419.
14. Wilson PF, Schaefer EJ, Larson MG, Ordovas JM. Apolipoprotein E alleles and risk of coronary disease. Arterioscler Thromb Vasc Biol 1996; 16:1250-5.
15. McKay GJ, Silvestri G, Chakravarthy U, Dasan S, Fritsche LG, Weber BH, et al. Variations in apolipoprotein E frequency with age in a pooled analysis of a large group of older people. Am J Epidemiol 2011; 173:1357-64.
16. Gerdes LU, Gerdes C, Kervinen K, Savolainen M, Klausen IC, Hansen PS, et al. The apolipoprotein "4 allele determines prognosis and the effect on prognosis of simvastatin in survivors of myocardial infarction. Circulation 2000; 101:1366-71.
17. Zamrini E, McGwin G, Roseman JM. Association between statin use and Alzheimer's disease. Neuroepidemiology 2004; 23:94-8.
18. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM. The Rotterdam Study. Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. J Neurol Neurosurg Psychiatry 2009; 80:13-7.
19. McGuiness B, Craig D, Bullock R, Passmore P. Statins for the prevention of dementia. Cochrane Database Syst Rev 2009; 2: CD003160.
20. Trompet S, van Vliet P, de Craen AJ, Jolles J, Buckley BM, Murphy MB, et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 2010; 257:85-90.
21. Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, van Dyck CH, et al. A randomised, double-blind, placebocontrolled trial of simvastatin to treat Alzheimer disease. Neurology 2011; 77:556-63.
22. Feldmann HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al. Randomized trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 2010; 74:956-64.
23. Strandberg TE. Lipid-lowering drugs and heart failure: Where do we go after the statin trials? Curr Opin Cardiol 2010; 25:385-93.